Global Benign Prostatic Hyperplasia Testing Market Growth (Status and Outlook) 2023-2029

Global Benign Prostatic Hyperplasia Testing Market Growth (Status and Outlook) 2023-2029

Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of the prostate doubles and the second growth phase starts at 25 years and continues throughout the lifetime. While the prostate gland enlarges in a man, it presses and pinches the urethra making the bladder wall thick. This pressure and squeeze on the urethra weaken the bladder and makes it lose the ability to empty the urine completely. Urinary retention and narrowing of the urethra can cause many problems which are associated with benign prostatic hyperplasia. Benign prostatic hyperplasia is one of the common prostate problems for men older than age 50.

LPI (LP Information)' newest research report, the “Benign Prostatic Hyperplasia Testing Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hyperplasia Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia Testing sales for 2023 through 2029. With Benign Prostatic Hyperplasia Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia Testing industry.

This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Benign Prostatic Hyperplasia Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia Testing.

The global Benign Prostatic Hyperplasia Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Benign prostatic hyperplasia testing market is primarily driven by a few key factors such as the growing geriatric male population, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure, increasing government initiatives and availability of minimally invasive surgery as a drug replacement, faster and easy performing diagnosis test results. The market is likely to grow owing to the novel diagnostic methods which are accurate than the conventional PSA blood test for benign prostatic hyperplasia which is effective in diagnosis and is expected to fuel the growth of benign prostatic hyperplasia testing market.

This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia Testing market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Urinalysis
Prostate-Specific Antigen (PSA) Blood Test
Urodynamic Test
Cystoscopy

Segmentation by application
Hospitals
Diagnostic Centers
Clinics
Research Institutes

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech

Please note: The report will take approximately 2 business days to prepare and deliver.